Brief: Resverlogix Reaches Agreement With FDA For Key Aspects Of Apabetalone Registration Enabling Study
22/06/2020 12:30
Resverlogix Corp RVX.TO :
* RESVERLOGIX REACHES AGREEMENT WITH FDA FOR KEY ASPECTS OF
APABETALONE REGISTRATION ENABLING STUDY
* RESVERLOGIX - NDA WITH FDA IS POSSIBLE AFTER UNEQUIVOCAL
EFFICACY AT INTERIM ANALYSIS OF BETONMACE2
Source text for Eikon: ID:nGNX4xzPN2
Further company coverage: RVX.TO
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment